INMB News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IN

Mkt Cap

$43.7M

Volume

190.77K

Next Earnings

October 29th

Loading chart

IN

INMBINmune Bio Inc. Common stock

INMB

Pay with—

Available Balance0.00

IN

Mkt Cap

$45.8M

Volume

190.77K

Next Earnings

October 29th

Chart Financials Earnings News About Insider Filings

INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's TrialINmune Bio announced statistically significant results from its Phase 2 MINDFuL trial of XPro1595 in early Alzheimer's disease patients. The drug showed a significant treatment effect on white matter myelin (p=0.0028) in the full study population (n=200) and strengthened further in inflammation-enriched patients (p=0.0098). The company has secured FDA Fast Track designation and End-of-Phase 2 alignment for an integrated Phase 2b/3 registrational program.GlobeNewswire Inc. · Jun 2, 2026

INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ PlatformINmune Bio Inc. (NASDAQ: INMB) announced that Phase 2 MINDFuL trial results for XPro™ (XPro1595, pegipanermin) in mild Alzheimer's disease with inflammation have been published in NPJ Dementia. In a pre-specified enriched subgroup (n=100) with amyloid-beta positivity and inflammation biomarkers, XPro™ showed directionally consistent benefits across cognitive, functional, behavioral, and biomarker endpoints over 24 weeks with no serious adverse events. The company received FDA Fast Track designation for the program.GlobeNewswire Inc. · May 15, 2026

INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's DiseaseINmune Bio announced that the FDA has granted Fast Track designation to XPro (pegipanermin), a first-in-class selective soluble TNF inhibitor, for treating early Alzheimer's disease including mild cognitive impairment and mild dementia. The designation facilitates expedited development and review, recognizing the urgent need for treatments addressing neuroinflammation in Alzheimer's. The company plans to execute a Phase 2b/3 precision-medicine registrational program targeting patients with biomarkers of inflammation.GlobeNewswire Inc. · May 14, 2026

INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business UpdateINmune Bio announced Q1 2026 financial results showing a net loss of $5.4 million, down from $9.7 million in Q1 2025. The company made progress on its CORDStrom™ platform with a planned UK MAA submission in mid-summer, advanced XPro™ to an adaptive Phase 2b/3 registrational pathway for early Alzheimer's Disease, and reported new preclinical data for INB03 in breast cancer. The company had $21.4 million in cash as of May 7, 2026.GlobeNewswire Inc. · May 7, 2026

INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7thINmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company focused on inflammation and immunology, announced it will host a conference call on May 7th, 2026 at 4:30 PM ET to discuss Q1 2026 financial results and provide a corporate update. The company is developing treatments targeting the innate immune system across three product platforms: CORDStrom, XPro, and INKmune.GlobeNewswire Inc. · Apr 30, 2026

INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s DiseaseINmune Bio's Phase 2 MINDFuL trial of XPro (pegipanermin) will be featured at the AD/PD 2026 conference as a successful example of biomarker enrichment strategy in Alzheimer's drug development. The trial showed consistent efficacy signals in inflamed patient subgroups, and the company has received FDA alignment to advance to a Phase 2b/3 registrational program for early Alzheimer's patients with inflammatory biomarkers.GlobeNewswire Inc. · Mar 19, 2026

Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ PlatformA peer-reviewed study published in Cytotherapy explores the potential of mesenchymal stromal cell (MSC) therapies, focusing on systemic delivery, local delivery methods, and in vivo persistence of cell treatments.GlobeNewswire Inc. · Dec 5, 2025

INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7thINmune Bio Inc. will host a conference call on August 7th, 2025 at 4:30pm EDT to discuss Q2 2025 financial results and provide a corporate update, focusing on their clinical-stage inflammation and immunology research.GlobeNewswire Inc. · Jul 31, 2025

INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30thINmune Bio will host a conference call on June 30, 2025, to present top line data from their Phase 2 MINDFuL trial investigating XPro™ treatment for early Alzheimer's Disease, focusing on patients with mild cognitive impairment and neuroinflammation markers.GlobeNewswire Inc. · Jun 26, 2025

Inmune Bio re-elects directors, ratifies auditor - Investing.comInmune Bio, a biopharmaceutical company, held its annual stockholders meeting, resulting in the re-election of its board of directors and the ratification of its independent auditor for the upcoming fiscal year.Investing.com · Jul 19, 2024

to start trading

IN

INMBINmune Bio Inc. Common stock

INMB

Pay with—

Available Balance0.00

Your PositionYou don't own any INMB yet.

Related Tickers

Earnings